NY-SPRINKLR
8.12.2020 10:02:06 CET | Business Wire | Press release
Sprinklr , the Customer Experience Management (CXM) platform for modern enterprises, today announced that Nordea , the largest financial services group in Northern Europe, is expanding its use of Sprinklr to deliver digital, personalized banking experiences.
After replacing legacy systems with Sprinklr three years ago because it needed a scalable platform, Nordea has grown its partnership with Sprinklr and is now leveraging four Sprinklr products to create a collaborative, company-wide digital banking strategy.
The Challenge: Growing Company, Changing Customer Behavior & Siloed Reporting
Corporate growth combined with a substantial increase in digital engagement , undefined marketing goals, and disconnected teams created an opportunity for Nordea to develop a strategic digital vision with strong execution capabilities.
The Solution: A Company-Wide Digital Banking Strategy on Sprinklr
Nordea’s marketing team, customer service department, and agencies collaborate in one Sprinklr platform.
With Sprinklr Modern Advertising , Nordea has a single source of truth for agencies and in-house teams to view real-time ad reporting data.
With benchmarking in Sprinklr Modern Research , Nordea can understand where they stand compared to competitors across countries, and can track trending topics and themes in Swedish, Norwegian, Finnish, Danish, and English. Nordea also works with Sprinklr to improve sentiment tracking for Nordic languages.
With Sprinklr Modern Care , the company has dramatically improved the efficiency of their support team. Nordea can use Sprinklr to easily understand if customers are asking questions about specific services – such as a business loan – and quickly connect them to the relevant care agent.
With Sprinklr Modern Engagement , Nordea has one content calendar to collaborate, publish, and plan marketing and engagement campaigns across Twitter, Facebook, Instagram, LinkedIn, and YouTube and answer inquiries on Google My Business and Trustpilot.
Comments on the News:
“Nordea is committed to being the bank of the future that our customers need,” said Elizabeth Fjellerup, Group CMO at Nordea. “Sprinklr provides us with a single platform to enhance every customer experience while empowering our teams to work together with the insights they need to make smart decisions.”
“Nordea is driving digital transformation forward within the financial services industry,” said Pavitar Singh, Chief Technology Officer, Sprinklr. “By implementing a single, companywide Sprinklr platform, Nordea has a clear understanding of its marketing and customer service performance along with deep customer insight. We’re proud to support Nordea’s commitment to delivering an easy digital banking experience.”
Additional Resources:
- Request a Sprinklr demo .
- Read Sprinklr Customer Stories .
About Sprinklr
Sprinklr (@Sprinklr ) is the world’s leading Customer Experience Management (CXM) platform. We help organizations reach, engage and listen to customers across 26 social channels, 11 messaging channels, and hundreds of millions of forums, blogs, and review sites. Sprinklr is a global company with 1,900 employees helping the world’s most valuable enterprises make their customers happier.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201208005160/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom